Hypercapnic Respiratory Failure
Conditions
Keywords
Acute on chronic respiratory failure, High-Flow heated and humidified nasal oxygen therapy
Brief summary
Chronic respiratory insufficiency and COPD are the third leading cause of death worldwide. Patients decompensate at various stages of their disease and exhibit acute-on-chronic respiratory failure (ACRF), a frequent cause of ICU hospitalization for hypercapnic acute respiratory failure (ARF). Non-invasive ventilation (NIV) is the first line ventilatory treatment for hypercapnic ARF. It is applied intermittently, separated by periods of spontaneous breathing (SB) with standard oxygen (O2). Standard O2 has drawbacks that limit the benefit of intermittent NIV in hypercapnic ARF: limited gas flow which is well below the patient's inspiratory flow rate, limited capacity and efficiency of oxygenation with non-controlled FiO2 (risk of excessive oxygen and induced hypercapnia), and cold and dry gas leading to discomfort and under-humidification of the airways and tracheobronchial secretions. Benefits in terms of work of breathing and CO2 removal resulting from PEEP and pressure support applied during NIV periods could be rapidly lost during standard O2. Recently, use of high-flow heated and humidified nasal oxygen therapy (HFHO) has gained enthusiasm among intensivists to manage ARF. HFHO delivers high flows (up to 60L/min, that generate moderate PEEP) of heated and humidified oxygen at a controlled and adjustable FiO2 (21 to 100%) that rapidly improve respiratory distress symptoms, oxygenation, respiratory comfort and outcome of patients with hypoxemic ARF. These unique features of HFHO could overcome some of the drawbacks of standard O2 during SB periods in hypercapnic ARF. Indeed, PEEP effect, washout of nasopharyngeal dead-space limiting CO2 re-breathing and inspired gas conditioning preserving adequate mucosal function and secretion removal, could potentially contribute to decrease airways resistance, intrinsic PEEP and work of breathing, while improving patient comfort. Investigators aim to determine if the use of HFHO, as compared to standard O2, increases the number of ventilator-free days (VFDs) and alive at day 28 in patients with hypercapnic ARF admitted in an ICU, an intermediate care, or a respiratory care unit, and requiring NIV.
Detailed description
In both groups, treatment will start with a first NIV session of 2 hours, with arterial blood gas measurement between one hour and two hours after initiating the NIV session. The NIV will be extended for those patients with a pH \< 7.30. In both groups, patients will be assessed for their tolerance of NIV and their ability to switch to spontaneous breathing every hour +/- 30 min, except during sleep (10 pm-8 am); they will be assessed for their tolerance of spontaneous breathing and for the need of resumption of NIV every 2 hours+/- 30 min and every 4 +/- 1 hours thereafter. To ensure the consistency of indications of NIV and invasive mechanical ventilation (IMV) across centers and reduce potential bias, NIV and IMV will be initiated and stopped in the same way in the two groups, using predefined criteria. * Inclusion (day 0): informed consent, randomisation (HFHO group/standard O2 group), NIV initiation (for 2 hours), clinical and paraclinical exam including ABG, data collection * Follow-up (day 1 to day 28) : NIV, clinical exam, ABG, data collection
Interventions
DEVICEHFHO Group
* Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases * Brand name: Airvo 2
DEVICEStandard O2
Standard oxygen therapy
Sponsors
Direction Générale de l'Offre de Soins
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients aged 18 or above, admitted to an ICU, an intermediate care or a respiratory care unit; * Chronic respiratory disease previously documented or strongly suspected on clinical, radiological and blood gazes data and pulmonary function tests, in connection with an obstructive respiratory disease (COPD, emphysema, overlap-syndrome (COPD + obstructive sleep apnoea) or mixed (bronchiectasis, obesity-hypoventilation syndrome)) * Patients requiring NIV for hypercapnic ARF (whatever the precipitating cause) i.e. with clinical signs of moderate to severe respiratory distress : dyspnea and /or respiratory rate \> 25/min and/or use of accessory respiratory muscles and/or paradoxical abdominal motion and/or signs of respiratory encephalopathy (sleepiness, asterixis, confusion); and respiratory acidosis on arterial blood gases, defined by pH\<7.35 and PaCO2 \> 45 mmHg despite the careful supply of oxygen and appropriate therapy that may include bronchodilators, corticosteroids and antibiotics
Exclusion criteria
* Contraindications to NIV; * Purely restrictive lung disease (thoracic deformity, neuro-muscular pathology) and pure obstructive sleep apnoea (without spirometric disturbance or daytime gas anomaly) * Immediate need for intubation (respiratory or cardiac arrest); * Persistent hemodynamic instability (use of vasopressors for \> 1 hour); * Multiple organ failure (score SOFA\>6); * NIV treatement for \>3 consecutive hours (without any interruption) before admission to ICU, intermediate care, or respiratory care unit and before randomization; * Anticipated difficulties to conduct NIV (facial trauma or deformation, edentulous patient); * End stage chronic respiratory insufficiency (defined as use of NIV at home or CPAP treatment at home and life expectancy below 6 month); * Non-treated pneumothorax; * Impossibility to perform subjective assessment of dyspnea and comfort (cognitive impairment); * Patient under guardianship or trusteeship; * Pregnancy/breastfeeding; * Decision to withhold or to withdraw life-sustaining treatments (including intubation) * Moribund state * Current participation in another clinical trial with an endpoint related to NIV. * No affiliation to social security (beneficial or assignee); * Refusal to participate to the study (patient or legal representative or family member or close relative if present
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of ventilator-free days (VFDs) alive | At day 28 after study enrollment |
Secondary
| Measure | Time frame |
|---|---|
| Patient self-assessement of comfort during each SB period measured by Visual Analog Scale (score range 0-10, higher values represent a better outcome) | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter, up to 28 days |
| Nurse assessement of comfort during each SB period measured by Likert scale (score range1-5; higher values represent a better outcome) | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter, up to 28 days |
| Hospital length of stay | 28 days post-randomisation |
| All cause mortality | 28 days post-randomisation |
| Proportion of patients with facial skin erythema and/or ulceration | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days |
| Number of NIV sessions | 28 days post-randomisation |
| Duration of NIV sessions (hours) | 28 days post-randomisation |
| Number of days between the day the patient first meets criteria for NIV cessation and day 28 post-randomization | 28 days post-randomisation |
| Number of days between the day of initially achieving unassisted ventilation and day 28 post-randomization (i.e. after having successfully spent 48 consecutive hours of unassisted breathing) | 28 days post-randomisation |
| Proportion of patients achieving 48 consecutive hours of daytime unassisted breathing | 28 days post-randomisation |
| Proportion of patients requiring NIV resumption after 48 consecutive hours of daytime unassisted breathing | 28 days post-randomisation |
| Patient self-assessement of comfort during each NIV period measured by Visual Analog Scale (score range 0-10, higher values represent a better outcome) | after 1 hour of NIV, up to 28 days |
| Nurse assessement of comfort during each NIV period measured by Likert scale (score range1-5; higher values represent a better outcome) | after 1 hour of NIV, up to 28 days |
| Patient self-assessement of dyspnea during each SB period measured by Visual Analog Scale (range 0-10; higher values represent a worst outcome) | after 2 hours of SB in the 48 first hours, and every 4 hours thereafter, up to 28 days |
| Nurse assessement of dyspnea during each SB period measured by Likert scale (score range1-5; higher values represent a worst outcome) | after 2 hours of SB in the 48 first hours, and every 4 hours thereafter, up to 28 days |
| Patient self-assessement of dyspnea during each NIV period measured by Visual Analog Scale (range 0-10; higher values represent a worst outcome) | after 1 hour of NIV, up to 28 days |
| Nurse assessement of dyspnea during each NIV period measured by Likert scale (score range1-5; higher values represent a worst outcome) | after 1 hour of NIV, up to 28 days |
| Delay of completion of stopping rules for NIV | 28 days post-randomisation |
| Respiratory rate during NIV periods | after 1 hour of NIV, up to 28 days |
| Proportion of patients using accessory muscles during NIV periods | after 1 hour of NIV, up to 28 days |
| Daily arterial blood gases (ABG) (in terms of pH, PaCO2 and PaO2 measured between 8-10 am). | up to 28 days post-randomisation |
| Proportion of patients with premature NIV cessation (intolerance) (defined by agitation and/or mask removal, and/or patient's wish to interrupt session before) | 28 days post-randomisation |
| Proportion of patients refusing to resume NIV (despite meeting criteria) | 28 days post-randomisation |
| Proportion of patients who need secondary intubation and IMV | 28 days post-randomisation |
| Proportion of patients with nasal bridge ulceration | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days |
| Proportion of patients with eye irritation | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days |
| Proportion of patients with nasal congestion | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days |
| Proportion of patients with nasal/oral dryness | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days |
| Proportion of patients with gastric distension | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days |
| Proportion of patients with nosocomial pneumonia | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days |
| Proportion of patients with pneumothorax | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days |
| Proportion of patients with arterial hypotension | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days |
| Proportion of patients with nostril ulceration (including nasolabial angle, columella, nostril sill) | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days |
| Proportion of patients with nose bleeding | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days |
| Respiratory rate during SB periods | after 2 hours of SB in the 48 first hours, and every 4 hours thereafter, up to 28 days |
Countries
France
Outcome results
None listed